Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > U.S. lawmakers to investigate approval, pricing of Alzheimer

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Jun 27, 2021 5:05am

187 Views

Post# 33457185

RE:RE:RE:RE:U.S. lawmakers to investigate approval, pricing of Alzheimer

Very interesting (lol)

Did a search to see where we stand with our competition....

What is the track record for predictions for these guys?

A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Status: Not Yet Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2021

Price : $35 *

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

DrugsACU 193 (Primary)
IndicationsAlzheimer's disease; Cognition disorders; Dementia
FocusAdverse reactions; Therapeutic Use
SponsorsAcumen Pharmaceuticals
- 24 Jun 2021New trial record
- http s://adisinsight.springer.com/trials/700338732